Obesity Pharmacotherapy

The Duke Clinical Research Institute hosted a think tank, "Anti-Obesity Pharmacotherapy: Need for Guidance, Access, and Equity" in October 2024. This brought together multi-industry stakeholders to align and advance the field of obesity medications (OMs). Key themes included the need for an evidence-based, patient-centric definition of obesity incorporating alternative measures of excess or dysfunctional adiposity, obesity symptoms, and obesity-related complications; barriers to OM access (cost and availability) that perpetuate inequalities in care; ambiguity in optimal clinical OM use; challenges of novel clinical trial designs; and ethics of placebo-controlled trials. Action items included a cross-stakeholder obesity research roadmap, standardized obesity measures inclusive of and beyond body mass index, strategies to ensure equitable OM access, and a forum to address regulatory and payer challenges. The complex, rapidly developing field of obesity research and OM development requires a strategy to ensure equitable, streamlined research and access to OMs.

Authors

Institutions

Publication Details

Journal
JACC Advances
Published
2026-04-01
DOI
https://doi.org/10.1016/j.jacadv.2026.102713
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Obesity Pharmacotherapy

Ania M. Jastreboff, Javed Butler, Jyothis T. George, Pishoy Gouda et al.
JACC Advances
Pharmacology and Obesity Treatment
article

Obesity Pharmacotherapy

Ania M. Jastreboff, Javed Butler, Jyothis T. George, Pishoy Gouda, Jennifer Jackman, Ruth M. Belin, Maria Borentain, Joanne Waldstreicher, Jingyu Julia Luan, Mariell Jessup, Christoph P. Hornik, Lesley H. Curtis, Paul Kessler, Nadine Allyn, D H Ryan, Brad Jordan, Sarah Wells Kocsis, Latoya Lartey, Neha Pagidipati
article en

Abstract

The Duke Clinical Research Institute hosted a think tank, "Anti-Obesity Pharmacotherapy: Need for Guidance, Access, and Equity" in October 2024. This brought together multi-industry stakeholders to align and advance the field of obesity medications (OMs). Key themes included the need for an evidence-based, patient-centric definition of obesity incorporating alternative measures of excess or dysfunctional adiposity, obesity symptoms, and obesity-related complications; barriers to OM access (cost and availability) that perpetuate inequalities in care; ambiguity in optimal clinical OM use; challenges of novel clinical trial designs; and ethics of placebo-controlled trials. Action items included a cross-stakeholder obesity research roadmap, standardized obesity measures inclusive of and beyond body mass index, strategies to ensure equitable OM access, and a forum to address regulatory and payer challenges. The complex, rapidly developing field of obesity research and OM development requires a strategy to ensure equitable, streamlined research and access to OMs.

JACC Advances
Pennington Biomedical Research Center (US), American Heart Association (US), Milken Institute (US), Becton Dickinson (United States) (US), Bayer (United States) (US), Eli Lilly (United States) (US), Yale University (US), University of Mississippi (US), Clinical Research Institute (US), Bristol-Myers Squibb (United States) (US), Parkinson's UK (GB), AstraZeneca (United States) (US), Boehringer Ingelheim (United States) (US), Baylor Scott & White Health (US)
Partnerships for the goals
Openalex Percentile: Top 28%
Pharmacology and Obesity Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.